Bilgin, B. Et Al. 2021. The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.9 , 2637-2643.

Bilgin, B., Sendur, M. A. N., Yucel, S., Hizal, M., GÜNER, G., AKYÜREK, N., ... Erol, C.(2021). The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.9, 2637-2643.

Bilgin, BURAK Et Al. "The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.9, 2637-2643, 2021

Bilgin, BURAK Et Al. "The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.9, pp.2637-2643, 2021

Bilgin, B. Et Al. (2021) . "The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.147, no.9, pp.2637-2643.

@article{article, author={BURAK BİLGİN Et Al. }, title={The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2021, pages={2637-2643} }